Eric Bellissant
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Eric Bellissant has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
- Djillali Annane
Service de Réanimation, Comprehensive Sepsis Centre PROMETHEUS, Hôpital Raymond Poincaré, Assistance Publique-Hôpitaux de Paris, Université Versailles Saint-Quentin, Garches, Versailles, France
3 shared publications Véronique Sébille
Centre d'Investigation Clinique INSERM 0203, Unité de Pharmacologie Clinique, Hôpital de Pontchaillou, Université de Rennes 1, 35033 Rennes, France
3 shared publications- Alain Cariou
Cochin University Hospital (AP-HP) and University Paris Cité (Medical School), Paris, France
2 shared publications - Alain Renault
Service de Pharmacologie, Centre d’Investigation Clinique INSERM 1414, CHU de Rennes, Université de Rennes 1, Rennes, France
2 shared publications - Benoit Misset
Intensive Care Department and Burn Centre, University Hospital of Liège, University of Liège, 4000 Liège, Belgium
2 shared publications - Blandine Lehmann
Département des Essais Cliniques, AGEPS, Paris, France
2 shared publications
Latest Publications
- 28 June 2022
- Published by Elsevier in Journal of Trace Elements in Medicine and Biology
- Vol. 73, 127031
Delayed increase of plasma selenoproteins and absence of side effect induced by infusion of pharmacological dose of sodium selenite in septic shock: Secondary analysis of a multicenter, randomized controlled trial
- 28 June 2022
- Published by Elsevier in Journal of Trace Elements in Medicine and Biology
- Vol. 73, 127031
Delayed increase of plasma selenoproteins and absence of side effect induced by infusion of pharmacological dose of sodium selenite in septic shock: Secondary analysis of a multicenter, randomized controlled trial
- Open Access
- 2 February 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (3) , 1490
Melatonin: From Pharmacokinetics to Clinical Use in Autism Spectrum Disorder
The role of melatonin has been extensively investigated in pathophysiological conditions, including autism spectrum disorder (ASD). Reduced melatonin secretion has been reported in ASD and led to many clinical trials using immediate-release and prolonged-release oral formulations of melatonin. However, melatonin’s effects in ASD and the choice of formulation type require further study. Therapeutic benefits of melatonin on sleep disorders in ASD were observed, notably on sleep latency and sleep quality. Importantly, melatonin may also have a role in improving autistic behavioral impairments. The objective of this article is to review factors influencing treatment response and possible side effects following melatonin administration. It appears that the effects of exposure to exogenous melatonin are dependent on age, sex, route and time of administration, formulation type, dose, and association with several substances (such as tobacco or contraceptive pills). In addition, no major melatonin-related adverse effect was described in typical development and ASD. In conclusion, melatonin represents currently a well-validated and tolerated treatment for sleep disorders in children and adolescents with ASD. A more thorough consideration of factors influencing melatonin pharmacokinetics could illuminate the best use of melatonin in this population. Future studies are required in ASD to explore further dose-effect relationships of melatonin on sleep problems and autistic behavioral impairments.
- 2 February 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (3) , 1490
Open AccessMelatonin: From Pharmacokinetics to Clinical Use in Autism Spectrum Disorder
The role of melatonin has been extensively investigated in pathophysiological conditions, including autism spectrum disorder (ASD). Reduced melatonin secretion has been reported in ASD and led to many clinical trials using immediate-release and prolonged-release oral formulations of melatonin. However, melatonin’s effects in ASD and the choice of formulation type require further study. Therapeutic benefits of melatonin on sleep disorders in ASD were observed, notably on sleep latency and sleep quality. Importantly, melatonin may also have a role in improving autistic behavioral impairments. The objective of this article is to review factors influencing treatment response and possible side effects following melatonin administration. It appears that the effects of exposure to exogenous melatonin are dependent on age, sex, route and time of administration, formulation type, dose, and association with several substances (such as tobacco or contraceptive pills). In addition, no major melatonin-related adverse effect was described in typical development and ASD. In conclusion, melatonin represents currently a well-validated and tolerated treatment for sleep disorders in children and adolescents with ASD. A more thorough consideration of factors influencing melatonin pharmacokinetics could illuminate the best use of melatonin in this population. Future studies are required in ASD to explore further dose-effect relationships of melatonin on sleep problems and autistic behavioral impairments.
- Open Access
- 1 January 2016
- Published by Elsevier in Annals of Intensive Care
- Vol. 6 (1) , 79-3
Erratum to: Design and conduct of the activated protein C and corticosteroids for human septic shock (APROCCHSS) trial
- 1 January 2016
- Published by Elsevier in Annals of Intensive Care
- Vol. 6 (1) , 79-3
Open AccessErratum to: Design and conduct of the activated protein C and corticosteroids for human septic shock (APROCCHSS) trial
- Open Access
- 1 January 2016
- Published by Elsevier in Annals of Intensive Care
- Vol. 6 (1) , 43-13
Design and conduct of the activated protein C and corticosteroids for human septic shock (APROCCHSS) trial
- 1 January 2016
- Published by Elsevier in Annals of Intensive Care
- Vol. 6 (1) , 43-13
Open AccessDesign and conduct of the activated protein C and corticosteroids for human septic shock (APROCCHSS) trial
- 1 June 2014
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 63 (6) , 488-496
Fludrocortisone and Hydrocortisone, Alone or in Combination, on In Vivo Hemodynamics and In Vitro Vascular Reactivity in Normal and Endotoxemic Rats
International audienceHydrocortisone enhances the pressor response to catecholamines in healthy volunteers and septic shock patients. Similar data do not exist for fludrocortisone. We assessed the effects of single administrations of fludrocortisone and hydrocortisone on systolic blood pressure until 2 hours after treatments injection and on in vitro vascular contraction of mesenteric artery rings to phenylephrine at 3 hours, in normal and endotoxemic rats. Intravenous fludrocortisone (5 and 20 μg/kg) and hydrocortisone (4 and 20 mg/kg) were administered in 16 groups (8 without and 8 with lipopolysaccharide-induced endotoxemic shock) of 10 Wistar rats according to four 2 × 2-factorial designs. Fludrocortisone and hydrocortisone similarly increased systolic blood pressure (P \textless 0.001 for both) but more in endotoxemic than in normal animals. Fludrocortisone and hydrocortisone significantly modified contractile response to phenylephrine (P = 0.039 and P = 0.007, respectively). At dose 1, fludrocortisone had no effect and hydrocortisone decreased contraction, whereas, at dose 2, both fludrocortisone and hydrocortisone increased contraction, especially in endotoxemic rats and with additive effect. Our results show that single intravenous administrations of fludrocortisone and hydrocortisone increase blood pressure and contractile response of mesenteric arteries to phenylephrine. The magnitude of these effects depends on dose and pathophysiological conditions and is higher in endotoxemic than in normal rats
- 1 June 2014
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 63 (6) , 488-496
Fludrocortisone and Hydrocortisone, Alone or in Combination, on In Vivo Hemodynamics and In Vitro Vascular Reactivity in Normal and Endotoxemic Rats
International audienceHydrocortisone enhances the pressor response to catecholamines in healthy volunteers and septic shock patients. Similar data do not exist for fludrocortisone. We assessed the effects of single administrations of fludrocortisone and hydrocortisone on systolic blood pressure until 2 hours after treatments injection and on in vitro vascular contraction of mesenteric artery rings to phenylephrine at 3 hours, in normal and endotoxemic rats. Intravenous fludrocortisone (5 and 20 μg/kg) and hydrocortisone (4 and 20 mg/kg) were administered in 16 groups (8 without and 8 with lipopolysaccharide-induced endotoxemic shock) of 10 Wistar rats according to four 2 × 2-factorial designs. Fludrocortisone and hydrocortisone similarly increased systolic blood pressure (P \textless 0.001 for both) but more in endotoxemic than in normal animals. Fludrocortisone and hydrocortisone significantly modified contractile response to phenylephrine (P = 0.039 and P = 0.007, respectively). At dose 1, fludrocortisone had no effect and hydrocortisone decreased contraction, whereas, at dose 2, both fludrocortisone and hydrocortisone increased contraction, especially in endotoxemic rats and with additive effect. Our results show that single intravenous administrations of fludrocortisone and hydrocortisone increase blood pressure and contractile response of mesenteric arteries to phenylephrine. The magnitude of these effects depends on dose and pathophysiological conditions and is higher in endotoxemic than in normal rats
- 10 January 2013
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 75 (2) , 423-430
Low doses of fludrocortisone and hydrocortisone, alone or in combination, on vascular responsiveness to phenylephrine in healthy volunteers
Aims: A single administration of hydrocortisone has been shown to enhance the pressor response to phenylephrine in healthy volunteers and to norepinephrine in septic shock patients. Similar data do not exist for fludrocortisone. Since there continues to be disagreement about the utility of fludrocortisone in septic shock, we assessed the effects of a single administration of low doses of hydrocortisone (50 mg intravenously) and fludrocortisone (50 μg orally), given either alone or in combination, on phenylephrine mean arterial pressure and cardiac systolic and diastolic function dose–response relationships in 12 healthy male volunteers with hypo‐aldosteronism induced by intravenous sodium loading.Methods: This was a placebo‐controlled, randomized, double‐blind, crossover study performed according to a 2 × 2 factorial design. Subjects received first a 2000 ml infusion ofNaCl0.9% during 2 h. Then fludrocortisone 50 μg (or its placebo) was administered orally and hydrocortisone 50 mg (or its placebo) was injected intravenously. At 1.5 h after treatment administration, incremental doses of phenylephrine were infused (from 0.01 to 3 μg kg−1 min−1), each dose being infused during 5 min.Results: Both fludrocortisone (P< 0.001) and hydrocortisone (P= 0.002) induced a significant decrease in pressor response to phenylephrine, their effects being additive (fludrocortisone × hydrocortisone interaction,P= 0.792). The two drugs did not induce any detectable cardiac effect.Conclusions: Single administrations of fludrocortisone and hydrocortisone decreased the pressor response to phenylephrine in healthy volunteers with hypo‐aldosteronism. These similar effects of hydrocortisone and fludrocortisone probably express a rapid non‐genomic vasodilating effect of the two steroids in the context of acute volume loading.
- 10 January 2013
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 75 (2) , 423-430
Low doses of fludrocortisone and hydrocortisone, alone or in combination, on vascular responsiveness to phenylephrine in healthy volunteers
Aims: A single administration of hydrocortisone has been shown to enhance the pressor response to phenylephrine in healthy volunteers and to norepinephrine in septic shock patients. Similar data do not exist for fludrocortisone. Since there continues to be disagreement about the utility of fludrocortisone in septic shock, we assessed the effects of a single administration of low doses of hydrocortisone (50 mg intravenously) and fludrocortisone (50 μg orally), given either alone or in combination, on phenylephrine mean arterial pressure and cardiac systolic and diastolic function dose–response relationships in 12 healthy male volunteers with hypo‐aldosteronism induced by intravenous sodium loading.Methods: This was a placebo‐controlled, randomized, double‐blind, crossover study performed according to a 2 × 2 factorial design. Subjects received first a 2000 ml infusion ofNaCl0.9% during 2 h. Then fludrocortisone 50 μg (or its placebo) was administered orally and hydrocortisone 50 mg (or its placebo) was injected intravenously. At 1.5 h after treatment administration, incremental doses of phenylephrine were infused (from 0.01 to 3 μg kg−1 min−1), each dose being infused during 5 min.Results: Both fludrocortisone (P< 0.001) and hydrocortisone (P= 0.002) induced a significant decrease in pressor response to phenylephrine, their effects being additive (fludrocortisone × hydrocortisone interaction,P= 0.792). The two drugs did not induce any detectable cardiac effect.Conclusions: Single administrations of fludrocortisone and hydrocortisone decreased the pressor response to phenylephrine in healthy volunteers with hypo‐aldosteronism. These similar effects of hydrocortisone and fludrocortisone probably express a rapid non‐genomic vasodilating effect of the two steroids in the context of acute volume loading.
- 15 May 2012
- Published by Springer Nature in Intensive Care Medicine
- Vol. 38 (8) , 1306-1314
Gluco- and mineralocorticoid biological effects of a 7-day treatment with low doses of hydrocortisone and fludrocortisone in septic shock
The benefits of low-dose steroids in septic shock remain controversial. We investigated if these low doses were able to induce their expected hormonal effects by analyzing the biological modifications observed during the study, which first demonstrated the survival benefit of low-dose steroids. This was a multicenter, placebo-controlled, randomized, double-blind study in which 299 septic shock patients received a 7-day treatment with a combination of hydrocortisone (50 mg intravenously four times daily) and fludrocortisone (50 μg orally once daily) or matching placebos. Gluco- and mineralocorticoid biological effects observed during the 7 days of treatment were compared between groups. Steroids significantly decreased eosinophil counts from day 2 to day 7. Steroids significantly increased plasma glucose from day 2 (compared with placebos: +0.8 mmol/l) to day 7 (+1.8 mmol/l) and cholesterol from day 3 (+0.54 mmol/l) to day 7 (+0.39 mmol/l). Steroids significantly increased plasma sodium from day 3 (+2 mmol/l) to day 7 (+5 mmol/l) and significantly decreased plasma potassium on day 7 (-0.2 mmol/l). Steroids significantly decreased urinary sodium/potassium ratio from day 2 (-47 %) to day 7 (-57 %) and sodium fractional excretion from day 3 (-25 %) to day 7 (-66 %). Steroids significantly increased urine output on day 4 and 5 and osmolar clearance from day 4 to day 7, and decreased free-water clearance from day 4 to day 7, this effect being significant on day 4 and 6. In septic shock, low-dose steroids induced both gluco- and mineralocorticoid biological effects and seemed to improve renal function. Most of these effects appeared after 2-3 days of treatment and lasted at least until the end of treatment.
- 15 May 2012
- Published by Springer Nature in Intensive Care Medicine
- Vol. 38 (8) , 1306-1314
Gluco- and mineralocorticoid biological effects of a 7-day treatment with low doses of hydrocortisone and fludrocortisone in septic shock
The benefits of low-dose steroids in septic shock remain controversial. We investigated if these low doses were able to induce their expected hormonal effects by analyzing the biological modifications observed during the study, which first demonstrated the survival benefit of low-dose steroids. This was a multicenter, placebo-controlled, randomized, double-blind study in which 299 septic shock patients received a 7-day treatment with a combination of hydrocortisone (50 mg intravenously four times daily) and fludrocortisone (50 μg orally once daily) or matching placebos. Gluco- and mineralocorticoid biological effects observed during the 7 days of treatment were compared between groups. Steroids significantly decreased eosinophil counts from day 2 to day 7. Steroids significantly increased plasma glucose from day 2 (compared with placebos: +0.8 mmol/l) to day 7 (+1.8 mmol/l) and cholesterol from day 3 (+0.54 mmol/l) to day 7 (+0.39 mmol/l). Steroids significantly increased plasma sodium from day 3 (+2 mmol/l) to day 7 (+5 mmol/l) and significantly decreased plasma potassium on day 7 (-0.2 mmol/l). Steroids significantly decreased urinary sodium/potassium ratio from day 2 (-47 %) to day 7 (-57 %) and sodium fractional excretion from day 3 (-25 %) to day 7 (-66 %). Steroids significantly increased urine output on day 4 and 5 and osmolar clearance from day 4 to day 7, and decreased free-water clearance from day 4 to day 7, this effect being significant on day 4 and 6. In septic shock, low-dose steroids induced both gluco- and mineralocorticoid biological effects and seemed to improve renal function. Most of these effects appeared after 2-3 days of treatment and lasted at least until the end of treatment.
- Open Access
- 13 December 2010
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 170 (22) , 2021-2027
Tamsulosin Hydrochloride vs Placebo for Management of Distal Ureteral Stones
Urinary stone disease is a common and increasing condition that affects 5% to 15% of the population in Europe and North America.1-3 Its optimal management is usually based on the site and size of the stone.4,5 Most ureteral calculi are small (5 For these patients, spontaneous passage rates of 71% to 98% have been reported.5 Thus, conservative therapy is indicated if pain can be controlled and if there is no evidence of infection. Medical expulsive therapy, using calcium channel blockers or adrenergic α-blockers, has also been proposed as a way to enhance ureteral stone passage.6 Indeed, ureteral smooth muscle relaxes in response to calcium channel blockers, and high densities of α1a-receptors and α1d-receptors have been shown in the distal third and ureterovesical junction of the ureteral smooth muscle.7-9 Therefore, α-adrenergic receptor antagonists decrease intraureteral pressure and increase fluid transport. Among these antagonists, tamsulosin hydrochloride seems to be selective and particularly interesting for medical expulsive therapy.10,11
- 13 December 2010
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 170 (22) , 2021-2027
Open AccessTamsulosin Hydrochloride vs Placebo for Management of Distal Ureteral Stones
Urinary stone disease is a common and increasing condition that affects 5% to 15% of the population in Europe and North America.1-3 Its optimal management is usually based on the site and size of the stone.4,5 Most ureteral calculi are small (5 For these patients, spontaneous passage rates of 71% to 98% have been reported.5 Thus, conservative therapy is indicated if pain can be controlled and if there is no evidence of infection. Medical expulsive therapy, using calcium channel blockers or adrenergic α-blockers, has also been proposed as a way to enhance ureteral stone passage.6 Indeed, ureteral smooth muscle relaxes in response to calcium channel blockers, and high densities of α1a-receptors and α1d-receptors have been shown in the distal third and ureterovesical junction of the ureteral smooth muscle.7-9 Therefore, α-adrenergic receptor antagonists decrease intraureteral pressure and increase fluid transport. Among these antagonists, tamsulosin hydrochloride seems to be selective and particularly interesting for medical expulsive therapy.10,11
- 11 August 2009
- Published by Taylor & Francis in Expert Opinion on Drug Metabolism & Toxicology
- Vol. 5 (11) , 1455-1468
Clinical pharmacology, efficacy and safety of atazanavir: a review
Background: Atazanavir (ATV) is a potent and safe protease inhibitor (PI) initially approved in adult HIV-1 infected patients in combination with other antiretroviral drugs with once daily administration. In combination with nucleoside reverse transcriptase inhibitors (NRTIs) and boosted with ritonavir, it has been established as the preferred initial regimen in published guidelines. Objective: This article reviews relevant pharmacodynamic, pharmacokinetic, efficacy and safety data of ATV, administered boosted with ritonavir or unboosted, in comparison with other PIs and/or non-NRTIs, with special focus on recent studies. Methods: Review articles, recent primary literature and scientific meeting reports were analyzed. Results: Compared to most PIs with similar efficacy, the advantages of ATV are a once daily administration with only 100 mg ritonavir when boosted, a good gastrointestinal tolerance with limited diarrhea, a neutral effect on cholesterol and triglycerides, and a favorable resistance profile. However, highly frequent hyperbilirubinemia is observed resulting in some cases in clinical jaundice. Unboosted ATV must be cautiously used because increased resistances have been described. Conclusion: The combination of a similar efficacy, a better tolerance and a low pill burden, as compared to other PIs, makes boosted ATV one of the best options, in combination with NRTIs, in PI-naive HIV-1 infected patients.
- 11 August 2009
- Published by Taylor & Francis in Expert Opinion on Drug Metabolism & Toxicology
- Vol. 5 (11) , 1455-1468
Clinical pharmacology, efficacy and safety of atazanavir: a review
Background: Atazanavir (ATV) is a potent and safe protease inhibitor (PI) initially approved in adult HIV-1 infected patients in combination with other antiretroviral drugs with once daily administration. In combination with nucleoside reverse transcriptase inhibitors (NRTIs) and boosted with ritonavir, it has been established as the preferred initial regimen in published guidelines. Objective: This article reviews relevant pharmacodynamic, pharmacokinetic, efficacy and safety data of ATV, administered boosted with ritonavir or unboosted, in comparison with other PIs and/or non-NRTIs, with special focus on recent studies. Methods: Review articles, recent primary literature and scientific meeting reports were analyzed. Results: Compared to most PIs with similar efficacy, the advantages of ATV are a once daily administration with only 100 mg ritonavir when boosted, a good gastrointestinal tolerance with limited diarrhea, a neutral effect on cholesterol and triglycerides, and a favorable resistance profile. However, highly frequent hyperbilirubinemia is observed resulting in some cases in clinical jaundice. Unboosted ATV must be cautiously used because increased resistances have been described. Conclusion: The combination of a similar efficacy, a better tolerance and a low pill burden, as compared to other PIs, makes boosted ATV one of the best options, in combination with NRTIs, in PI-naive HIV-1 infected patients.
- Open Access
- 1 December 2005
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 76 (12) , 1670-1676
Placebo controlled, randomised, double blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patients
Objective: The purpose of the study was to evaluate the efficacy and safety of botulinum A toxin in the treatment of detrusor sphincter dyssynergia in multiple sclerosis patients. Methods: This was a multicentre, placebo controlled, randomised, double blind study. Patients with chronic urinary retention were included if they had post-voiding residual urine volume between 100 and 500 ml. They received a single transperineal injection of either botulinum A toxin (100 U Allergan) or placebo in the sphincter and also 5 mg slow release alfuzosin bid over 4 months. Main endpoint was post-voiding residual urine volume assessed 1 month after injection. Follow up duration was 4 months. Statistical analysis was performed using a sequential method, the triangular test. Results: The study was stopped after the fourth analysis (86 patients had been included: placebo: 41, botulinum A toxin: 45). At inclusion, there was no significant difference between groups whichever variable was considered. Mean (standard deviation) post-voiding residual urine volume was 217 (96) and 220 (99) ml in placebo and botulinum A toxin groups, respectively. One month later, post-voiding residual urine volume was 206 (145) and 186 (158) ml (p = 0.45) in placebo and botulinum A toxin groups, respectively. However, compared to placebo, botulinum A toxin significantly increased voiding volume (+54%, p = 0.02) and reduced pre-micturition (−29%, p = 0.02) and maximal (−21%, p = 0.02) detrusor pressures. Other secondary urodynamic endpoints and tolerance were similar in the two groups. Conclusions: In multiple sclerosis patients with detrusor sphincter dyssynergia, a single injection of botulinum A toxin (100 U Allergan) does not decrease post-voiding residual urine volume.
- 1 December 2005
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 76 (12) , 1670-1676
Open AccessPlacebo controlled, randomised, double blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patients
Objective: The purpose of the study was to evaluate the efficacy and safety of botulinum A toxin in the treatment of detrusor sphincter dyssynergia in multiple sclerosis patients. Methods: This was a multicentre, placebo controlled, randomised, double blind study. Patients with chronic urinary retention were included if they had post-voiding residual urine volume between 100 and 500 ml. They received a single transperineal injection of either botulinum A toxin (100 U Allergan) or placebo in the sphincter and also 5 mg slow release alfuzosin bid over 4 months. Main endpoint was post-voiding residual urine volume assessed 1 month after injection. Follow up duration was 4 months. Statistical analysis was performed using a sequential method, the triangular test. Results: The study was stopped after the fourth analysis (86 patients had been included: placebo: 41, botulinum A toxin: 45). At inclusion, there was no significant difference between groups whichever variable was considered. Mean (standard deviation) post-voiding residual urine volume was 217 (96) and 220 (99) ml in placebo and botulinum A toxin groups, respectively. One month later, post-voiding residual urine volume was 206 (145) and 186 (158) ml (p = 0.45) in placebo and botulinum A toxin groups, respectively. However, compared to placebo, botulinum A toxin significantly increased voiding volume (+54%, p = 0.02) and reduced pre-micturition (−29%, p = 0.02) and maximal (−21%, p = 0.02) detrusor pressures. Other secondary urodynamic endpoints and tolerance were similar in the two groups. Conclusions: In multiple sclerosis patients with detrusor sphincter dyssynergia, a single injection of botulinum A toxin (100 U Allergan) does not decrease post-voiding residual urine volume.